A Hundred Years of Diagnosing Superficial Fungal Infections: Where Do We Come From, Where Are We Now and Where Would We Like To Go?

被引:23
作者
Graeser, Yvonne [1 ,2 ,3 ,4 ]
Saunte, Ditte Marie Lindhardt [5 ,6 ,7 ]
机构
[1] Charite Univ Med Berlin, Inst Microbiol & Infect Immunol, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Berlin Inst Hlth, Natl Reference Lab Dermatophytes, Berlin, Germany
[5] Zealand Univ Hosp, Dept Dermatol, Roskilde, Denmark
[6] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[7] Statens Serum Inst, Dept Bacteria Parasites & Fungi, Unit Mycol, Copenhagen, Denmark
关键词
diagnostic; microscopy; PCR; dermatophytes; dermatomycoses; DESORPTION-IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; TINEA-CAPITIS; IDENTIFICATION; DERMATOPHYTES; ONYCHOMYCOSIS; PERFORMANCE; MICROSCOPY; ASSAY; NAIL;
D O I
10.2340/00015555-3467
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Superficial fungal infections have been known for hundreds of years. During the 20th century new diagnostic methods were developed and the taxonomy changed several times, which, unfortunately, resulted in many fungi having several names (synonyms). The taxonomy is important, as species-specific identification guides clinicians when choosing the most appropriate antifungal agent, and provides an indication of the source of infection (anthropophilic, zoophilic or geophilic). Traditional diagnostic tests (direct microscopy, culture and histopathology) are still widely used, but molecular-based methods, such as PCR, have many advantages, and increasingly supplement or replace conventional methods. Molecular-based methods provide detection of different genus/species spectra. This paper describes recent changes in dermatophyte taxonomy, and reviews the currently available diagnostics tools, focusing mainly on commercially available PCR test systems.
引用
收藏
页码:216 / 224
页数:9
相关论文
共 50 条
[31]   Quality Improvement in Cytology Where Do We Go From Here? [J].
Renshaw, Andrew A. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2011, 135 (11) :1387-1390
[32]   Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going? [J].
Sloan, Anthony R. ;
Silver, Daniel J. ;
Kint, Sam ;
Gallo, Marco ;
Lathia, Justin D. .
NEURO-ONCOLOGY, 2024, 26 (05) :785-795
[33]   Line managers in industrial relations: Where are we now and where to next? [J].
Townsend, Keith ;
Hutchinson, Sue .
JOURNAL OF INDUSTRIAL RELATIONS, 2017, 59 (02) :139-152
[34]   Hot Topics in Recent Parkinson's Disease Research: Where We are and Where We Should Go [J].
Li, Song ;
Jia, Congcong ;
Li, Tianbai ;
Le, Weidong .
NEUROSCIENCE BULLETIN, 2021, 37 (12) :1735-1744
[35]   Terrestrial Locomotion-Where Do We Stand, Where Are We Going? An Introduction to the Symposium [J].
Blob, Richard W. ;
Higham, Timothy E. .
INTEGRATIVE AND COMPARATIVE BIOLOGY, 2014, 54 (06) :1051-1057
[36]   One century after Liepmann's work on apraxia: Where do we go now? [J].
Bartolo, Angela ;
Osiurak, Francois .
CORTEX, 2022, 154 :333-339
[37]   Social capital and community development: Where do we go from here? [J].
Halstead, John M. ;
Deller, Steven C. ;
Leyden, Kevin M. .
COMMUNITY DEVELOPMENT, 2022, 53 (01) :92-108
[38]   Visual fields in glaucoma: Where are we now? [J].
Lee, Graham A. ;
Kong, George Y. X. ;
Liu, Chun-Huei .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 51 (02) :162-169
[39]   Self-Assessments of Knowledge: Where Do We Go From Here? [J].
Bell, Bradford S. ;
Federman, Jessica E. .
ACADEMY OF MANAGEMENT LEARNING & EDUCATION, 2010, 9 (02) :342-347
[40]   Safety of creatine supplementation: where are we now? [J].
Machado, Marco ;
Guimaraes, Pablo ;
Forbes, Scott C. .
GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2022, 181 (7-8) :597-598